Literature DB >> 22346314

Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.

Maisha Kelly Freeman.   

Abstract

Entities:  

Year:  2011        PMID： 22346314      PMCID： PMC3278179     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  26 in total

1.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

2.  Burden of hospitalizations primarily due to uncontrolled diabetes: implications of inadequate primary health care in the United States.

Authors:  Sunny Kim
Journal:  Diabetes Care       Date:  2007-02-08       Impact factor: 19.112

3.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.

Authors:  S Hüttner; E U Graefe-Mody; B Withopf; A Ring; K A Dugi
Journal:  J Clin Pharmacol       Date:  2008-10       Impact factor: 3.126

4.  Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

Authors:  S Del Prato; A H Barnett; H Huisman; D Neubacher; H-J Woerle; K A Dugi
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

Review 5.  DPP-4 inhibitors: what may be the clinical differentiators?

Authors:  John Gerich
Journal:  Diabetes Res Clin Pract       Date:  2010-08-13       Impact factor: 5.602

6.  The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

Authors:  Arne Ring; Andreas Port; E Ulrike Graefe-Mody; Ivette Revollo; Mario Iovino; Klaus A Dugi
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 7.  Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

8.  Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

Authors:  T Heise; E U Graefe-Mody; S Hüttner; A Ring; D Trommeshauser; K A Dugi
Journal:  Diabetes Obes Metab       Date:  2009-05-19       Impact factor: 6.577

9.  (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Authors:  Leo Thomas; Matthias Eckhardt; Elke Langkopf; Moh Tadayyon; Frank Himmelsbach; Michael Mark
Journal:  J Pharmacol Exp Ther       Date:  2008-01-25       Impact factor: 4.030

10.  Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.

Authors:  Aberra Fura; Ashish Khanna; Viral Vyas; Barry Koplowitz; Shu-Ying Chang; Christian Caporuscio; David W Boulton; Lisa J Christopher; Kristina D Chadwick; Lawrence G Hamann; W Griffith Humphreys; Mark Kirby
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.